Mohamed Ibrahim Bassyouni
2020 / 5 / 23
Corona vaccine, developed in China, bodes well after studying over 100 people. The vaccine seemed safe and capable of generating an immune response.
A new study showed that a possible coronavirus vaccine developed in China seemed safe and capable of generating an immune response after an early trial in more than 100 people.
The vaccine, called Ad5-nCoV, is being developed by the Chinese company CanSino Biologics, and was one of the first coronavirus vaccines to enter early human trials in March. Now, there are more than 100 different coronavirus vaccines under development worldwide, with at least eight of those undergoing human trials.
Ad5-nCoV uses a weak version of the common cold virus (known as adenovirus) that infects human cells but does not cause disease to provide part of the genetic material from SARS-CoV-2, the virus that causes COVID-19. This genetic material provides signals and instructions for making "Spike protein" on the surface of SARS - CoV-2. The idea is that a person s immune system will create antibodies to the protein spike, which will help fight the coronavirus if it is subsequently exposed.
In a new study published Friday (May 22) in The Lancet, researchers tested Ad5-nCoV in 108 healthy people between the ages of 18 and 60 who did not have COVID-19. Participants received either a low, medium,´-or-high dose of vaccine.
Two weeks after vaccination, participants in the three groups demonstrated a level of immune response to the virus. By 28 days, almost all participants developed SARS-CoV-2 antibodies (but not necessarily attacking the virus), and about half of the participants in the low and medium dose groups and three quarters of the high dose group participants developed "neutral antibodies" associated with the virus and mal-function-ed to prevent it From hitting cells.
The study indicated that the most common side effects were mild pain at the injection site, mild fever, fatigue, headache, and muscle pain.
However, nine participants (two in the low-dose group, two in the medium-dose group and five in the high-dose group) had a fever greater than 38.5 ° C, and symptoms developed in one participant in the high-dose group severe fever with fatigue, shortness of breath and muscle pain. However these effects lasted for no more than 48 hours.
Participants were aware of the dose they received, which may have influenced their perceptions of side effects.
"These results are an important milestone," but the results should be interpreted with caution, said Wei Chen, senior researcher with the study from the Beijing Institute of Biotechnology in China. The challenges in developing a COVD-19 vaccine are unprecedented, and the ability to stimulate these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19.